EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

How I treat patients with AML using azacitidine and venetoclax

Andrew H Wei iD, Sun Loo iD, Naval Daver iD

Blood · 20.03.2025 · 145 (12) · 1237-1250

DOI: 10.1182/blood.2024024009 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Blood, erschienen am 20.03.2025. Verfasst von Andrew H Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax (VEN) received full approval in October 2020 for use in older patients who are unfit with acute myeloid leukemia (AML) combined with either hypomethylating agents or low-dose cytarabine. This ended a semicentennial of stalled clinical progress and initiated a new treatment option with proven capacity to enhance response and prolong survival in older patients with AML. Despite widespread use of azacitidine-VEN (AZA-VEN), there is increasing appreciation that this regimen is myelosuppressive and associated with a higher risk of infectious complications than AZA alone. Key principles of initial management include prevention of tumor lysis syndrome in patients at high risk and minimizing infectious complications during induction. In the postremission phase, limiting cumulative marrow suppression by allowing sufficient time between cycles for optimal marrow recovery and truncating the duration of VEN exposure for those with delayed blood count recovery have emerged as important axioms of effective care. This article casts a clinical spotlight on important challenges and dilemmas encountered in practice. We also outline a structured framework to assist in the safe management of AZA-VEN in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemale

Substanzen

venetoclaxAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Australia.
  • Department of Haematology, Northern Hospital, Epping, VIC, Australia.
  • Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Andrew H Wei, Sun Loo, Naval Daver

Zitieren

APA

Wei, A. H., Loo, S., & Daver, N. (2025). How I treat patients with AML using azacitidine and venetoclax. Blood, 145(12), 1237-1250. https://doi.org/10.1182/blood.2024024009

Vancouver

Wei AH, Loo S, Daver N. How I treat patients with AML using azacitidine and venetoclax. Blood. 2025;145(12):1237-1250. doi:10.1182/blood.2024024009

BibTeX
@article{Wei2025,
  author = {Wei, Andrew H and Loo, Sun and Daver, Naval},
  title = {How I treat patients with AML using azacitidine and venetoclax},
  journal = {Blood},
  year = {2025},
  volume = {145},
  number = {12},
  pages = {1237--1250},
  doi = {10.1182/blood.2024024009}
}
Kostenlos starten →